Vaccentis strengthens leadership with appointment of Mario

• Life science govt with expertise in ophthalmology, branding, advertising and marketing and financing
• Will lead gross sales and advertising and marketing of medicines for dry eye and autoimmune illnesses

Zurich, Switzerland, September 8, 2022 – Vaccentis AG, a clinical-stage Swiss biopharmaceutical firm growing patient-specific medicines, as we speak introduced the appointment of the skilled life science govt Mario Stark as Chief Sales and Marketing Officer, efficient instantly.

Mario Stark has in-depth experience normally administration, advertising and marketing, innovation, and product administration and joins Vaccentis from his most up-to-date function as CEO of digital well being firm Vivior. During his profession, he has efficiently arrange, financed and led organizations to develop novel applied sciences and companies. He beforehand based and led Solianis Monitoring, elevating capital from personal buyers and enterprise capital funds to develop progressive expertise for diabetes administration, oversaw a turnaround at Pendragon Medical as Chief Operating Officer, and spent 9 years in senior roles at Sulzer Orthopedics, together with advertising and marketing and expertise.

“I am very pleased to welcome Mario Stark to Vaccentis as Chief Sales and Marketing Officer. Mario brings a wealth of experience in the pharma and biotech market and in this role, he will modernize the sales and marketing efforts of our FBM-Pharma business, selling complementary medicines for dry eye and various autoimmune diseases. Mario’s expertise, particularly in ophthalmology, and his strengths in leadership of global organizations, marketing, brand management and raising capital make him perfectly suited to lead this effort as we work in parallel to optimize and increase our manufacturing and distribution capabilities,” mentioned Martin Munte, CEO of Vaccentis.

It additional strengthens Vaccentis’ govt leadership crew, following the appointment of the skilled biotech chief Martin Munte as CEO in July. Three high-profile entrepreneurs, Matthias Oertle, Marcel Frei and Subhasis Roy, joined the Board of Directors in May, with Matthias Oertle serving as Chairman.

“I am excited to join Vaccentis at this important moment in its development, as it is poised for a new phase of growth. I look forward to working with the talented leadership team to expand our revenues and support the development of a very promising pipeline,” mentioned Mario Stark.

Vaccentis AG is a clinical-stage Swiss biopharmaceutical firm growing patient-specific medicines to enhance sufferers’ probabilities of restoration from power and malignant illnesses. Vaccentis’ product pipeline contains Reniale®, Autologous Serum Eye Drops (ASAT), Individual Immunotherapy, and Urexent®. Reniale is in scientific growth to deal with non-metastatic renal cell carcinomas; ready from the sufferers’ tumors, it stimulates the immune system to assault tumor cells and reduces the chance of recurrence and metastases. ASAT is an environment friendly remedy of dry eye illnesses ready from the affected person’s blood. Research suggests it might be simpler and higher tolerated than conventional tear alternative merchandise.

Contact: